GE HealthCare (GEHC) reported a 6% growth in revenues in its third quarter of 2025, citing performance driven by its Imaging, Advanced Visualization Solutions, and Pharmaceutical Diagnostics segments.
For the period (end-September 30), GEHC had total revenues of $5.1 billion, up from $4.7 billion in the same period last year. The company’s net income for the quarter was $446 million, versus $470 million for the prior year, while its adjusted EBIT (Earnings Before Interest and Taxes) was $761 million, versus $795 million in the previous year. Both net income and EBIT were impacted by tariffs, but were partially offset by benefits from sales volume and price, the company said.
On an individual segment basis, the company had growth across all segments: Imaging revenue was up 5% to $2.3 billion from $2.2 billion in the same period last year; Advanced Visualization Solutions grew 7% to $1.3 billion in revenue; and Pharmaceutical Diagnostics revenue jumped 20% to $749 million. Meanwhile, the company’s cash flow from operating activities was $593 million, down $149 million year-over-year.
Among recent innovations and commercial highlights, GEHC noted its recent agreement through CDL Nuclear Technologies Group to distribute its PET myocardial perfusion imaging agent Flyrcado in the U.S. and a licensing agreement to develop, manufacture, and commercialize Lantheus’ PET radiotracer F-18 piflufolastat in Japan.
